Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
INC. DSS,, a 10% owner of $IBO, sold 53,280 shares of the company on 03-20-2025 for an estimated $249,350. We received data on the trade from a recent SEC filing ...
We recently published a list of 10 Micro-, Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where Impact Biomedical Inc. (NYSEAMERICAN:IBO) stands against ...
Short interest in Impact BioMedical Inc (AMEX:IBO) increased during the last reporting period, rising from 254.22K to 667.07K. This put 9.96% of the company's publicly available shares short. Short ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Chan Heng Fai, a director at Impact Biomedical Inc. (NASDAQ:IBO), has sold 351,555 shares of the company's common stock. The stock... ByInvesting.com • 07 Apr 2025 Impact Biomedical sees $1.12 million ...
Impact BioMedical (IBO) stock skyrocketed on Monday after the specialty biopharmaceutical and consumer healthcare company announced a merger agreement with Hong Kong-based pharmaceutical company Dr ...
Explore Impact BioMedical analyst ratings and price targets (AMEX:IBO) on Benzinga. Stay updated on expert opinions and forecasts for IBO stock. There is no next analyst rating for Impact BioMedical.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results